Connecticut

Psychedelic trials in Connecticut

77 registered trials has a study site in Connecticut, and 16 are recruiting now.

Trials with a site here

Recruiting

Facilities

Open now

Recruiting in this state

Trial	Status	Phase	Substance	Sites
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397 · Cybin IRL Limited	Recruiting	Phase 3	psilocybin	68
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence StudyNCT06713616 · Yale University	Recruiting	Phase 3	ketamine	8
MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use DisorderNCT07118839 · VA Office of Research and Development	Recruiting	Phase 2 / Phase 3	mdma	2
The Efficacy of Psilocybin Therapy for Depression in Parkinson's DiseaseNCT07610369 · Yale University	Recruiting	Phase 2	psilocybin	1
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal EffectsNCT05786066 · Yale University	Recruiting	Phase 2	ketamine	1
Imaging Depression in Parkinson's DiseaseNCT06402955 · Yale University	Recruiting	Phase 2	ketamine	1
MDMA in Borderline Personality DisorderNCT06683014 · Yale University	Recruiting	Phase 2	mdma	1
Enhancing Week-long Psychological Treatment for PTSD With KetamineNCT05737693 · Yale University	Recruiting	Phase 2	ketamine	2
The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)NCT06070649 · Yale University	Recruiting	Phase 1	dmt	1
Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)NCT06160284 · Yale University	Recruiting	Phase 1	psilocybin	1
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in HumansNCT06671977 · Deepak C. D'Souza	Recruiting	Phase 1	dmt	1
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine ResponseNCT05915013 · Yale University	Recruiting	Phase 1	ketamine	1
Open-Label Psilocybin Study in Transdiagnostic PopulationNCT06442423 · Yale University	Recruiting	Phase 1	psilocybin	1
Psilocybin as a Treatment for Chronic Pain in SmokersNCT07118332 · Yale University	Recruiting	Early Phase 1	psilocybin	2
Mechanistic Studies of Psilocybin in Headache DisordersNCT06464367 · Yale University	Recruiting	Early Phase 1	psilocybin	1
The OBSERVE ProtocolNCT06725277 · Yale University	Recruiting	N/A	ketamine	8

Facilities

Where the research happens in Connecticut

Facility	City	Trials
Yale University	New Haven	12
Connecticut Mental Health Center	New Haven	9
VA Connecticut Healthcare System	West Haven	6
VA Connecticut Healthcare System West Haven Campus, West Haven, CT	West Haven	4
Yale New Haven Hospital	New Haven	4
Yale School of Medicine	New Haven	3
Mood Institute	Milford	2
Yale University School of Medicine	New Haven	2
Department of Veterans Affairs	West Haven	2
Yale Child Study Center	New Haven	2
University of Connecticut	Farmington	2
VA Connecticut Healthcare System, West Haven Campus	West Haven	2
Pfizer Investigational Site	New Haven	2
Yale Psychiatry Hospital Interventional Psychiatry Services (IPS) unit	New Haven	2
Yale School of Medicine - Yale Program for Psychedelic Science	New Haven	1
Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,	West Haven	1
Connecticut Mental Health Center - Yale School of Medicine	New Haven	1
University of Connecticut Health Center	Farmington	1
CERC (VISN1, West Haven, CT)	West Haven	1
Hospital Research Unit at the Yale New Haven Hospital	New Haven	1
Comprehensive Psychiatric Care	Norwich	1
Connecticut Mental Health Center, Yale University	New Haven	1
University of Conneticut School of Medicine	Farmington	1
Individual homes of subjects	Not Predetermined	1
Institute of Living/ Hartford Hospital	Hartford	1
VA Healthcare System	West Haven	1
West Haven Veterans Affairs	West Haven	1
Connecticut Mental Health Center/ YNHH	New Haven	1
Enact Research Collaborative (40 Temple St, 4th Floor)	New Haven	1
Yale Program for Psychedelic Research	New Haven	1
Enact Research Collaborative	New Haven	1
Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine	West Haven	1
Lori Calabrese MD Innovative Psychiatry	South Windsor	1
Yale New Haven Hospital Emergency Department	New Haven	1
VA CT Healthcare Systems	West Haven	1
Yale Psychiatric Hospital	New Haven	1
VHA CT	West Haven	1
Olin Neuropsychiatry Research Center	Hartford	1
Yale Depression Research Program	New Haven	1
West Haven VA Medical Center	West Haven	1

Stay told

When a trial opens in Connecticut

All trials

Every trial with a Connecticut site

Trial	Status	Phase	Substance	Sites
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397 · Cybin IRL Limited	Recruiting	Phase 3	psilocybin	68
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence StudyNCT06713616 · Yale University	Recruiting	Phase 3	ketamine	8
MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use DisorderNCT07118839 · VA Office of Research and Development	Recruiting	Phase 2 / Phase 3	mdma	2
The Efficacy of Psilocybin Therapy for Depression in Parkinson's DiseaseNCT07610369 · Yale University	Recruiting	Phase 2	psilocybin	1
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal EffectsNCT05786066 · Yale University	Recruiting	Phase 2	ketamine	1
Imaging Depression in Parkinson's DiseaseNCT06402955 · Yale University	Recruiting	Phase 2	ketamine	1
MDMA in Borderline Personality DisorderNCT06683014 · Yale University	Recruiting	Phase 2	mdma	1
Enhancing Week-long Psychological Treatment for PTSD With KetamineNCT05737693 · Yale University	Recruiting	Phase 2	ketamine	2
The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)NCT06070649 · Yale University	Recruiting	Phase 1	dmt	1
Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)NCT06160284 · Yale University	Recruiting	Phase 1	psilocybin	1
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in HumansNCT06671977 · Deepak C. D'Souza	Recruiting	Phase 1	dmt	1
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine ResponseNCT05915013 · Yale University	Recruiting	Phase 1	ketamine	1
Open-Label Psilocybin Study in Transdiagnostic PopulationNCT06442423 · Yale University	Recruiting	Phase 1	psilocybin	1
Psilocybin as a Treatment for Chronic Pain in SmokersNCT07118332 · Yale University	Recruiting	Early Phase 1	psilocybin	2
Mechanistic Studies of Psilocybin in Headache DisordersNCT06464367 · Yale University	Recruiting	Early Phase 1	psilocybin	1
The OBSERVE ProtocolNCT06725277 · Yale University	Recruiting	N/A	ketamine	8
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant DepressionNCT04599855 · Janssen Research & Development, LLC	Completed	Phase 4	ketamine	54
VA Aripiprazole vs Esketamine for Treatment Resistant DepressionNCT05554627 · VA Office of Research and Development	Withdrawn	Phase 4	ketamine	26
Ketamine Infusion for Adolescent Depression and AnxietyNCT02579928 · Yale University	Completed	Phase 4	ketamine	2
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRDNCT05624268 · COMPASS Pathways	Completed	Phase 3	psilocybin	40
Psilocybin for Major Depressive Disorder (MDD)NCT06308653 · Usona Institute	Active, not recruiting	Phase 3	psilocybin	29
A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)NCT04077437 · Resilient Pharmaceuticals	Completed	Phase 3	mdma	14
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant DepressionNCT02422186 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	69
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant DepressionNCT02493868 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	155
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant DepressionNCT02497287 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	109
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant DepressionNCT02782104 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	173
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideNCT03039192 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	56
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideNCT03097133 · Janssen Research & Development, LLC	Completed	Phase 3	ketamine	61
ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)NCT03113968 · Bo Hu	Completed	Phase 2 / Phase 3	ketamine	5
Ketamine for Severe Adolescent Depression: Intermediate-term Safety and EfficacyNCT03889756 · Yale University	Terminated	Phase 2 / Phase 3	ketamine	1
Intranasal Ketamine In the Treatment of Pediatric Bipolar DisorderNCT01504659 · Juvenile Bipolar Research Foundation	Terminated	Phase 2 / Phase 3	ketamine	4
Psilocybin-Assisted Physical Therapy in Chronic Low Back PainNCT07306364 · Yale University	Not yet recruiting	Phase 2	psilocybin	1
A Study of Psilocybin for Major Depressive Disorder (MDD)NCT03866174 · Usona Institute	Completed	Phase 2	psilocybin	11
Ketamine for the Treatment of Depression in Parkinson's DiseaseNCT04944017 · Yale University	Completed	Phase 2	ketamine	1
Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous KetamineNCT04613453 · Yale University	Terminated	Phase 2	ketamine	1
Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSDNCT03282123 · Resilient Pharmaceuticals	Completed	Phase 2	mdma	12
A Study of Ketamine in Patients With Treatment-resistant DepressionNCT01627782 · Janssen Research & Development, LLC	Completed	Phase 2	ketamine	13
A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant DepressionNCT01998958 · Janssen Research & Development, LLC	Completed	Phase 2	ketamine	25
A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for SuicideNCT02133001 · Janssen Research & Development, LLC	Completed	Phase 2	ketamine	14
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for SuicideNCT03185819 · Janssen Research & Development, LLC	Completed	Phase 2	ketamine	51
Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use DisorderNCT02461927 · VA Office of Research and Development	Completed	Phase 1 / Phase 2	ketamine	1
Open Label Ketamine Treatment for Major Depressive Disorder in VeteransNCT03053830 · VA Connecticut Healthcare System	Completed	Phase 2	ketamine	1
Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure TherapyNCT02727998 · Yale University	Terminated	Phase 2	ketamine	1
CAP-Ketamine for Antidepressant Resistant PTSDNCT02655692 · VA Office of Research and Development	Completed	Phase 2	ketamine	3
Examining the Impact of Sirolimus on Ketamine's Antidepressant EffectsNCT02487485 · Yale University	Completed	Phase 2	ketamine	2
Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)NCT01920555 · Massachusetts General Hospital	Completed	Phase 2	ketamine	6
Ketamine Infusion for Obsessive-Compulsive DisorderNCT01349231 · Yale University	Completed	Phase 2	ketamine	1
The Effects of Psilocybin on Social ConnectednessNCT07693153 · Yale University	Not yet recruiting	Phase 1	psilocybin	1
Effects of Repeated Psilocybin Dosing in OCDNCT05370911 · Yale University	Active, not recruiting	Phase 1	psilocybin	2
The Effects of MDMA on Prefrontal and Amygdala Activation in PTSD.NCT03752918 · Yale University	Withdrawn	Phase 1	mdma	1
Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive DisorderNCT03554174 · Yale University	Active, not recruiting	Phase 1	psilocybin	1
Fixed Order, Open-Label, Dose-Escalation Study of DMT in HumansNCT04711915 · Yale University	Active, not recruiting	Phase 1	dmt	1
A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant DepressionNCT05268497 · Janssen Research & Development, LLC	Withdrawn	Phase 1	ketamine	5
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot TrialNCT03367533 · Yale University	Completed	Phase 1	ketamine	1
Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.NCT03356483 · Yale University	Completed	Phase 1	psilocybin	1
Repeat Dosing of Psilocybin in Migraine HeadacheNCT04218539 · Yale University	Completed	Phase 1	psilocybin	1
Psilocybin for the Treatment of Cluster HeadacheNCT02981173 · Yale University	Completed	Phase 1	psilocybin	1
Psilocybin for the Treatment of Migraine HeadacheNCT03341689 · Yale University	Completed	Phase 1	psilocybin	1
Effects of Psilocybin in Concussion HeadacheNCT03806985 · Yale University	Terminated	Phase 1	psilocybin	1
Modified Ketogenic Diet and Ketamine for Anorexia NervosaNCT04714541 · Homeostasis Therapeutics, LLC	Completed	Phase 1	ketamine	1
Ketamine for Low Mood States in the ERNCT01209845 · Yale University	Completed	Phase 1	ketamine	1
Ketamine for Depression and Alcohol DependenceNCT01551329 · Yale University	Completed	Phase 1	ketamine	1
A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy VolunteersNCT01749098 · Biogen	Completed	Phase 1	ketamine	2
Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous KetamineNCT02289248 · Yale University	Completed	Phase 1	ketamine	2
Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) AntagonismNCT02675530 · Yale University	Completed	Phase 1	ketamine	1
Psilocybin Microdosing on Cognition, Mood and Quality of LifeNCT07449351 · Yale University	Not yet recruiting	Early Phase 1	psilocybin	1
Examining The Effect Of Ketamine On Glutamate/Glutamine CyclingNCT02037035 · Yale University	Completed	Early Phase 1	ketamine	1
Ketamine Infusion for Social Anxiety DisorderNCT02083926 · Yale University	Completed	Early Phase 1	ketamine	1
Using Virtual Reality to Control the Audio-visual Inputs During Ketamine/Esketamine TreatmentNCT06139016 · Yale University	Completed	Not applicable	ketamine	1
Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic PsychedelicsNCT06624137 · Yale University	Terminated	N/A	lsd, psilocybin, dmt	2
Imaging SV2A in Mood DisordersNCT02734602 · Yale University	Active, not recruiting	Not applicable	ketamine	1
Role Of Non-Specific Effects in The Treatment of Depression With EsketamineNCT05910775 · Yale University	Terminated	Not applicable	ketamine	1
Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse PreventionNCT04760652 · Yale University	Completed	Not applicable	ketamine	3
Long Term Follow Up KET-PDNCT06164756 · Yale University	Enrolling by invitation	N/A	ketamine	1
Ketamine/Placebo Family History Positive StudyNCT00588952 · Yale University	Completed	Not applicable	ketamine	1
Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant DepressionNCT03027362 · Yale University	Completed	Not applicable	ketamine	1
PET Imaging of mGLuR5 With Drug ChallengeNCT01691092 · Yale University	Completed	Not applicable	ketamine	3

Site locations from ClinicalTrials.gov API v2, data build 2026-08-25.

Elsewhere